Product Overview
[Drug Name]
Generic Name: Dihydroergotoxine Methanesulfonate Sustained-Release Tablets
Trade Name: Yishujialin
English Name: Dihydroergotoxine Methanesulfonate Sustained-Release Tablets
Chinese Pinyin: JiaHuangSuanErQingMaiJiaoJianHuanShiPian (YiShuJiaLin)
[Ingredients] The main ingredient is dihydroergotoxine mesylate, which is composed of equal amounts of dihydroergocornine mesylate, dihydroergotine mesylate, and dihydroergocryptine mesylate.
[Properties]
This product is a white tablet with a score in the middle of one side.
[Indications]
Cerebral and peripheral vascular diseases.
[Dosage and Administration]
Oral administration: Take twice daily, one tablet in the morning and one tablet in the evening, after meals. Or as directed by a physician.
[Adverse Reactions]
1. Yishujialin (dihydroergotoxine mesylate) sustained-release tablets are generally well tolerated. 2. Initial use may occasionally result in transient nausea, stomach discomfort, vomiting, flushing, and postural hypotension.
[Contraindications]
This product is contraindicated in patients with allergies, hypotension, severe bradycardia, organic heart damage, renal impairment, or pregnant women.
[Precautions]
Esugaline (dihydroergotamine mesylate) extended-release tablets must be used under the guidance of a physician. Please read the instructions carefully and follow your physician's instructions.
[Special Population Use]
Precautions for Children:
This product is contraindicated (the safety and efficacy of this product in children have not been established).
Precautions for Pregnancy and Lactation:
Precautions for Pregnant Women:
This product is particularly effective in preventing and treating circulatory disorders in the elderly, especially those affecting the central nervous system.
[Drug Interactions]
This product has no drug interactions.
[Pharmacological Actions]
It improves neuronal metabolism. This product inhibits the activity of ATPase and adenylate cyclase, reducing the breakdown of ATP, improving energy balance in brain cells, and converting non-oxidative glucose into oxidative glucose. This improves glucose utilization, increasing neuronal energy, enhancing electrical activity, and improving microcirculation. This product directly acts on dopamine and serotonin receptors in the central nervous system, enhancing neurotransmitter release from presynaptic nerve endings and stimulation of postsynaptic receptors, thereby improving neurotransmission. It also blocks α-receptors, alleviating vasospasm and reducing vascular resistance, thereby increasing blood flow and oxygen utilization in the brain. It also increases the frequency and amplitude of α-waves in the electroencephalogram (EEG), thereby improving EEG abnormalities in the elderly.
Storage: Protect from light and store in a sealed container.
Strength: 2.5 mg
Packaging: 25 tablets/box.
Expiration Date: 24 months
Approval Number: National Medicine Standard H20093234
Manufacturer: Baolihua (Nanjing) Pharmaceutical Co., Ltd.
